[Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer].

Abstract

The pharmacokinetic of 5-Fluorouracil and its permeation into malignant pleural effusion was investigated in 9 patients with breast carcinoma who received 600 mg/m2 5-Fluorouracil i.v. within the CMF protocol. Despite the short plasma halflife of 5-Fluorouracil (16,8 min) distinct concentrations with peak levels up to 115 nmol/ml after 30 min were observed in the effusions. In consequence of the rapid elimination of 5-Fluorouracil from the plasma and the comparatively slow retrograde diffusion (t 1/2 55 min) from the pleural space, the drug levels persisted longer in the effusions, than in the blood. Thus the area under the curve of the pleural level (AUC) reached 50% (27-85%) of the corresponding plasma AUC (10,9 +/- 2,3 mumol x min x ml-1). From a pharmacokinetic point of view, no additional local instillations of 5-Fluorouracil are necessary during a systemic therapy of breast cancer with pleural effusions.

• Authors: T Wagner
• Journal: Onkologie (Onkologie) Vol. 7 Issue 1 Pg. 22-6 (Feb 1984) ISSN: 0378-584X [Print] Switzerland
• Vernacular Title: Die Pharmakokinetik von 5-Fluorouracil und seine Permeation in Pleuraergüsse bei der Therapie des metastasierenden Mamma-Karzinoms.
• PMID: 6369203 (Publication Type: English Abstract, Journal Article)

Chemical References

• Cyclophosphamide
• Fluorouracil
• Methotrexate

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols
• Biological Availability
• Breast Neoplasms (drug therapy)
• Chromatography, High Pressure Liquid
• Cyclophosphamide (therapeutic use)
• Female
• Fluorouracil (administration & dosage, blood, therapeutic use)
• Humans
• Kinetics
• Metabolic Clearance Rate
• Methotrexate (therapeutic use)
• Middle Aged
• Pleural Effusion (metabolism)
• Pleural Neoplasms (drug therapy, secondary)